Bluejay Diagnostics stock fell 1.12 percent on October 2

Published on 10/04/2026 at 19:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bluejay Diagnostics stock was last at USD 0.84 on Nasdaq on October 2, 2026. Q2 2026 cash reached USD 9.6 million while net loss was USD 2.3 million.

Bluejay, US0956336087, Illustration mit AI erstellt.

Bluejay Diagnostics stock (ISIN US0956336087) was last at USD 0.84 on Nasdaq on October 2, 2026 at 4:00 p.m. ET, down 1.12 percent from the prior session. The company is building a federal healthcare distribution route for its investigational Symphony platform, with regulatory clearance still required before U.S. commercialization.

Federal access meets regulatory risk

According to the SEC, Bluejay entered a distribution, co-marketing and strategic partnership with Lovell Government Services under an agreement dated September 1, 2026. The related release dated September 8, 2026 describes Lovell as the exclusive distributor for selected federal procurement opportunities, including channels linked to veterans and military healthcare.

The arrangement expands commercial preparation, but it does not create current product sales. StockTitan reported that the Symphony platform remains investigational and requires FDA authorization before it can be marketed in the United States.

Cash improves while losses continue

Bluejay ended Q2 2026 with USD 9.6 million in cash and reported a net loss of USD 2.3 million for the quarter, according to StockTitan. The Q2 loss compares with a USD 1.9 million net loss in Q1 2026, while operating cash flow was negative USD 1.5 million in Q2 versus negative USD 1.6 million in Q1.

The balance sheet therefore improved between March 31 and June 30, 2026, with cash rising from USD 3.7 million to USD 9.6 million. The same report said management expected the cash runway to extend into Q2 2027, giving the company additional time to advance its SYMON clinical program and regulatory plans.

Analyst view stays negative

MarketBeat lists one analyst rating for Bluejay Diagnostics as of October 4, 2026, with a Sell consensus. The page shows zero Buy ratings, zero Hold ratings and one Sell rating, while the consensus price target is unavailable.

That assessment frames the central tension in Bluejay's story: the company has strengthened liquidity, but the product remains pre-commercial and regulatory execution determines whether the federal distribution framework can become revenue. For investors, the USD 0.80 to USD 16.68 52-week range also underlines the stock's unusually wide trading history.

Bluejay Diagnostics stock stays near its yearly low

Bluejay Diagnostics stock was last at USD 0.84 on Nasdaq on October 2, 2026 at 4:00 p.m. ET, with a market capitalization of USD 0.9 million and volume of 114,844 shares. The price stood USD 0.04 above the 52-week low of USD 0.80.